AnthonyHunterMD
Hematology • Atlanta, GAHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Assistant Professor, Emory University School of Medicine, Winship Cancer Institute
Dr. Hunter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1365 Clifton Road
Winship Cancer Institute
Atlanta, GA 30322Phone+1 404-778-0519- Is this information wrong?
Education & Training
University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2017 - 2020
Emory University School of MedicineResidency, Internal Medicine, 2014 - 2017
Medical College of WisconsinClass of 2014
Certifications & Licensure
GA State Medical License 2020 - 2025
FL State Medical License 2017 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 8 citationsEvaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS).Andrew M Brunner, Alexander Gavralidis, Najla Al Ali, Anthony Hunter, Rami Komrokji, Amer Zeidan, David A Sallman> ;Blood Cancer Journal. 2022 Nov 15
- 3 citationsProgenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse Outcomes.Meghan C Ferrall-Fairbanks, Abhishek Dhawan, Brian Johnson, Hannah Newman, Virginia Volpe, Christopher Letson, Markus Ball, Anthony M Hunter, Maria E Balasis, Traci Kr...> ;Blood Cancer Discovery. 2022 Nov 2
- 1 citationsDifferential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia.Connor Walsh, Anthony Hunter, Terra Lasho, Christy Finke, Rhett Ketterling, Rami Komrokji, Ayalew Tefferi, Abhishek Mangaonkar, Matthew Howard, Naseema Gangat, Aref Al...> ;Leukemia. 2022 Jun 1
- Join now to see all
Abstracts/Posters
- Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell TransplantationAnthony Hunter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)Anthony M. Hunter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study ...Anthony M. Hunter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
A Legacy of TyrosineMay 11th, 2020
Hospital Affiliations
Emory University HospitalAtlanta, Georgia
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
